Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin

American Journal of Hematology

Volumn 81, Issue 3, 2006, Pages 199-201

  Curtis, Brian R ^a   Kaliszewski, James ^a   Marques, Marisa B ^b   Saif, M Wasif ^b   Nabelle, Lisle ^b   Blank, Jules ^c   McFarland, Janice G ^a   Aster, Richard H ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Green Bay Oncology   (United States)

Author keywords

Drug induced thrombocytopenia; Oxaliplatin; Platelet antibodies

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACTINOMYCIN; FIBRINOGEN RECEPTOR; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; OXALIPLATIN; RITUXIMAB; SURAMIN; THROMBOCYTE ANTIBODY;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CASE REPORT; COLON CARCINOMA; COLOSTOMY; DRUG INDUCED DISEASE; ECCHYMOSIS; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOCHEZIA; HEMATURIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE MEDIATED INJURY; MEGAKARYOCYTE; METASTASIS; ORAL BLEEDING; PETECHIA; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 33644550950     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20516     Document Type: Article

References (35)

1. Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;36:2-10.
2. Aster RH. Drug-induced thrombocytopenia. In: Michelson AD, editor. Platelets. New York: Academic Press; 2002. p 593-606.
3. Visentin JP, Wolfmeyer K, Newman PJ, Aster RH. Detection of drug-dependent platelet reactive antibodies by antigen-capture ELISA and flow cytometry. Transfusion 1990;30:694-700.
4. Curtis BR, McFarland JG, Wu GG, Visentin JP, Aster RH. Antibodies associated with sulfonamide-induced immune thrombocytopenia react preferentially with calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994;84:176-183.
5. Gentilini G, Curtis BR, Aster RH. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood 1998;92:2359-2365.
6. Menitove JE, Pereira J, Hoffman R, et al. Cyclic thrombocytopenia of apparent autoimmune etiology. Blood 1989;73: 1561-1569.
7. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-1218.
8. Getaz EP, Beckley S, Fitzpatrick J, Dozier A. Cisplatin-induced hemolysis. N Engl J Med 1980;302:334-335.
9. Maloisel F, Kurtz JE, Andres E, Gorodetsky C, Dufour P, Oberling F. Platin salts-induced hemolytic anemia: cisplatin and the first case of carboplatin-induced hemolysis. Anti-Cancer Drugs 1995;6:324-326.
10. Marani TM, Trich MB, Armstrong KS, et al. Carboplatin-induced immune hemolytic anemia. Transfusion 1996;36:1016-1018.
11. Garufi C, Vaglio S, Brienza S, et al. Immunohemolytic anemia following oxaliplatin administration. Ann Oncol 2000;11:497.
12. Desrame J, Broustet H, Darodes de Tailly P, Girard D, Saissy JM. Oxaliplatin-induced haemolytic anaemia. Lancet 1999;354: 1179-1180.
13. Sorbye H, Bruserud Y, Dahl O. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Acta Oncol 2001;40:882-883.
14. Chen VM, Thrift KM, Morel-Kopp MC, Jackson D, Ward CM, Flower RL. An immediate hemolytic reaction induced by repeated administration of oxaliplatin. Transfusion 2004;44:838-843.
15. Earle CC, Chen WY, Ryan DP, Mayer RJ. Oxaliplatin-induced Evans's syndrome. Br J Cancer 2001;84:441.
16. Dold FG, Mitchell EP. Sudden-onset thrombocytopenia with oxaliplatin. Ann Intern Med [letter] 2003;139:E156-E157.
17. Koutras AK, Makatsoris T, Paliogianni F, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004;67:179-182.
18. Mizushima Y, Morinaga S, Morikage T, Yano S. Sudden onset of thrombocytopenia after the treatment with chemotherapeutic agent(s) in a patient with lymphangitis carcinomatosa. Jpn J Med 1989;28:777-782.
19. Visentin GP, Newman JP, Aster RH. Characteristics of quinine-and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 1991;77:2668-2676.
20. Bougie DW, Birenbaum JA, Wilker PR, Aster RH. What targets are recognized by drug-dependent antibodies (DDAbs)? Blood 2003;102:538a.
21. Garratty G. Immune cytopenia associated with antibiotics. Transfusion Med Rev 1993;7:255-267.
22. Shulman NR. A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in auto-immunity. Ann Intern Med 1964;60:506-521.
23. Christie DJ, Mullen PC, Aster RH. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest 1985;75: 310-314.
24. Smith ME, Reid DM, Jones CE, Jordan JV, Kautz CA, Shulman NR. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest 1987;79: 912-917.
25. Mueller-Eckhardt C, Kuenzlen E, Kiefel V, Vahrson H, Graubner M. Cyclophosphamide-induced immune thrombocytopenia in a patient with ovarian carcinoma successfully treated with intravenous gamma globulin. Blut 1983;46:165-169.
26. Bozec L, Bierling P, Fromont P, et al. Irinotecan-induced immune thrombocytopenia. Ann Oncol 1998;9:453-455.
27. Seidman AD, Schwartz M, Reich L, Scher HI. Immune-mediated thrombocytopenia secondary to suramin. Cancer 1993;71: 851-854.
28. rd. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one. Am J Hematol 1996;51:152-157.
29. Shannon A, Smith J, Nagel K, Levesque R, Warkontin T, Barr R. Selective thrombocytopenia in children with Wilms tumor: an immune-mediated effect of dactinomycin? Med Pediatr Oncol 2003;41:483-485.
30. Khatua S, Nair CN, Ghosh K. Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues. J Pediatr Hematol Oncol 2004;26:777-779.
31. Fernandez MJ, Llopis I, Pastor E, Real E, Grau E. Immune thrombocytopenia induced by fludarabine successfully treated with rituximab. Haematologica 2003;88:ELT02.
32. Morgan M, Savdie E, Dodds A. Thrombocytopaenia as a complication of cyclosporine A therapy. Austr NZ J Med 1990;20:749.
33. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alcmtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004;9:409-411.
34. Shah C, Grethlein SJ. Case report of rituximab-induced thrombocytopenia. Am J Hematol 2004;75:263.
35. Pamuk GE, Donmez S, Turgut B, Demir M, Vural O. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 2005;78:81.